BUSINESS

More news
Revolution Medicines Stock Soars 39% on Daraxonrasib Pancreatic Cancer Survival

Revolution Medicines Stock Soars 39% on Daraxonrasib Pancreatic Cancer Survival Win

REDWOOD CITY, Calif. — Revolution Medicines Inc. shares skyrocketed nearly 39% Monday to $134.18, the biotech company's biggest one-day surge in years, after it announced that its lead drug daraxonrasib achieved an unprecedented overall survival benefit in a pivotal Phase 3 trial for patients with metastatic pancreatic cancer, a notoriously hard-to-treat disease with limited options.
The logo for Goldman Sachs is seen on the trading floor at the New York Stock Exchange (NYSE) in New York City

Goldman Sachs Beats Q1 Expectations with Record Trading Revenue but Shares Plunge 4% on Mixed Signals

NEW YORK — Goldman Sachs Group Inc. shares tumbled more than 4% in early trading Monday after the Wall Street giant reported stronger-than-expected first-quarter earnings powered by record equities trading and a rebound in investment banking fees, even as investors appeared to focus on broader market volatility and lingering concerns over private credit and geopolitical risks.
Google May Avoid Harsh Penalties as Judge Eyes Softer Antitrust

Alphabet Stock Dips in Pre-Market as AI Spending and Antitrust Pressures Weigh on GOOG

NEW YORK — Alphabet Inc. Class C shares closed Friday at $315.72, unchanged on the day, but slipped in pre-market trading Monday to around $313.60, down about 0.67%, as investors weighed heavy capital spending on artificial intelligence infrastructure against ongoing regulatory challenges and broader market caution tied to geopolitical tensions.
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA

Five Biggest Gainers in the S&P/ASX 200 on Monday, April 13, 2026

SYDNEY — Energy and healthcare names dominated the S&P/ASX 200's biggest gainers Monday as renewed uncertainty over the U.S.-Iran naval blockade in the Strait of Hormuz pushed oil prices higher, providing a modest cushion for resource-exposed stocks even as the broader index slipped 0.39% to close at 8,926.0.
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA

ASX 200 Drops 0.39% as Iran Ceasefire Fragility and Oil Volatility Weigh on Investors

SYDNEY — The S&P/ASX 200 index closed lower Monday, shedding 34.6 points or 0.39% to finish at 8,926.0 as renewed uncertainty over the fragile U.S.-Iran ceasefire and fluctuating oil prices rattled Australian investors. The benchmark slipped from Friday's close of 8,960.6, with the day's trading range stretching from a high of 8,960.6 to a low of 8,889.6 amid cautious sentiment across global markets.
Strait of Hormuz Remains Largely Closed Despite US-Iran Ceasefire as

Failed Hormuz Talks and Trump Blockade Trigger Global Stock Sell-Off as Oil Surges Past $103

NEW YORK — The abrupt failure of U.S.-Iran peace negotiations in Pakistan and President Donald Trump's immediate order to blockade the Strait of Hormuz sent shockwaves through world financial markets Monday, driving oil prices above $103 a barrel and triggering sharp declines in global stock indexes as investors priced in prolonged energy disruptions and higher inflation risks.
Applied Optoelectronics

Applied Optoelectronics Stock 2026: Buy the AI Optics Surge or Sell Before the Pullback?

SUGAR LAND, Texas — Applied Optoelectronics Inc. (NASDAQ: AAOI) has emerged as one of the hottest — and most volatile — plays in the artificial intelligence data center boom of 2026, with shares surging more than 1,140% over the past year to trade around $150 as of April 10. The company's aggressive push into high-speed 800G and 1.6T optical transceivers for hyperscale customers has fueled explosive revenue guidance, yet Wall Street analysts remain divided, with consensus price targets well below current levels and warnings of significant execution risks.
Organon & Co

Buy or Sell Organon Stock in 2026? Takeover Buzz Lifts Shares 28% as Analysts Stay Cautious

JERSEY CITY, N.J. — Shares of Organon & Co. surged more than 27% on April 10, 2026, closing at $8.83 after reports emerged that India's Sun Pharmaceutical Industries is nearing a potential $12 billion all-cash takeover offer for the women's health and biosimilars specialist, injecting fresh drama into a stock that has struggled with flat growth and heavy debt.
Nvidia's CEO Jensen Huang founded the chip giant three decades ago

NVIDIA Stock 2026: Buy or Sell NVDA as AI Demand and Blackwell Ramp Fuel Strong Buy Consensus

NEW YORK — NVIDIA Corp. (NASDAQ: NVDA) shares closed at approximately $188.63 on April 10, 2026, with Wall Street analysts maintaining a strong consensus "Buy" or "Strong Buy" rating as the company rides explosive demand for its AI GPUs, particularly the Blackwell platform, despite concerns over lofty valuations and potential slowdowns in hyperscaler capital spending.
Palantir

Palantir Stock 2026: Buy or Sell PLTR as AI Platform Drives 61% Revenue Growth Despite High Valuation Concerns

NEW YORK — Palantir Technologies Inc. (NASDAQ: PLTR) shares traded near $128 as of April 10, 2026, with Wall Street issuing a Moderate Buy consensus amid explosive commercial momentum from its Artificial Intelligence Platform (AIP) and steady government contract wins, though some analysts caution that the stock's premium valuation leaves limited room for error.
Fluence Energy Stock Jumps 7% as Battery Storage Leader Rides

Fluence Energy Stock Jumps 7% as Battery Storage Leader Rides AI Data Center Boom

NEW YORK — Fluence Energy Inc. shares climbed more than 7% in morning trading Friday, reaching $14.56 as investors bet on the battery storage company's strong positioning in the surging U.S. energy storage market fueled by artificial intelligence data centers, grid modernization and supportive domestic manufacturing policies.

Pages

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next